Chimso Okoji is an associate in the litigation and enforcement practice group. He focuses his practice on securities and complex commercial litigation, including securities class actions, corporate governance and shareholder disputes, M&A-related litigation, and post-closing disputes. Chimso also represents public companies, private equity sponsors and their portfolio companies, and individual directors and officers in SEC investigations and enforcement matters and has particular experience handling parallel regulatory and civil proceedings arising from the same events. He regularly works with deal teams to assess litigation risk in connection with public company transactions and advises acquirers on stockholder litigation, appraisal demands, and other post-closing claims.

Chimso maintains an active pro bono practice, representing clients in the District of Columbia courts, as well as federal district courts, in various criminal and civil matters. Prior to law school, Chimso worked as a senior legislative assistant in the United States House of Representatives for a New York member of Congress.

Experience

Securities and Corporate Governance Litigation

  • Represented a clinical-stage biotechnology company and certain of its executives in obtaining full dismissal of a federal putative securities class action asserting claims under Sections 10(b) and 20(a) of the Exchange Act concerning disclosures about investigational drug therapies. The dismissal is currently on appeal before the U.S. Court of Appeals for the First Circuit.
  • Advised a global pharmaceutical company on stockholder appraisal demands under Section 262 of the Delaware General Corporation Law arising from its acquisition of a public biotechnology company.
  • Defended public companies and their directors against disclosure-based stockholder suits and demand letters challenging merger proxy statements, including advising on disclosure strategy and resolution of related demands.
  • Advised acquirers, including in the life sciences sector, on litigation and regulatory diligence and on managing deal-related litigation risk in connection with public and private company acquisitions.
  • Represented Shari Redstone and National Amusements, Inc. against parallel actions in the Delaware Court of Chancery brought by former stockholders of Viacom and former stockholders of CBS challenging the multi-billion dollar merger of Viacom and CBS.
  • Represented a private Delaware LLC in a corporate governance dispute among board members and the company’s founder involving claims of wrongful termination and fraud.
  • Represented a private equity sponsor in expedited Delaware Court of Chancery merger litigation concerning the application of a “material adverse effect” clause to a public target’s performance between signing and closing.
  • Defended a chief executive officer in SEC litigation alleging insider trading.
  • Represented a former public company chief executive officer in securities and derivative litigation arising from a cybersecurity incident.
  • Represented an officer and director in advancement litigation, including on appeal to the Delaware Supreme Court.
  • Represented a former Chief Executive Officer in a derivative action asserting various breaches of fiduciary duties, including a Brophy claim under Delaware law.

Complex Commercial Litigation and Arbitration

  • Representing a private equity-backed technology company in a nationwide multidistrict litigation in federal court comprising consumer class actions and related claims.
  • Represented the buyer of a healthcare services business in Delaware Superior Court litigation brought by the seller concerning earnout payments under a securities purchase agreement.
  • Represented a private equity portfolio company in a JAMS Arbitration in connection with a post-closing dispute alleging breaches of representation and warranties.
  • Represented a private equity portfolio company in a state supreme court appeal of a breach of contract claim.
  • Represented one of the largest not-for-profit health insurers in a JAMS Arbitration alleging breach of contract and conversion.
  • Represented a pharmaceutical manufacturer in a qui tam action on appeal in the Ninth Circuit regarding the scope of liability for off-label promotion.
  • Represented a leading investment management firm in litigation alleging breaches of contract and fiduciary duty, conversion, and fraud.
  • Represented a biopharmaceutical company in a successful administrative appeal of an FDA decision.
  • Represented the Pharmaceutical Research and Manufacturers of America (PhRMA) as amicus curiae in the U.S. Supreme Court in a case concerning the False Claims Act.
  • Represented several mutual fund investment advisers against claims of excessive fees under Section 36(b) of the Investment Company Act.

Securities Enforcement

  • Represented a medical technology company and its senior executives in an SEC investigation concerning the company’s revenue recognition, quarter-end sales practices, and acquisition accounting, which concluded with the staff declining to recommend enforcement action.
  • Represented a clinical-stage biotechnology company in an SEC investigation, parallel to a related securities class action, concerning its disclosures regarding its drug candidates; the staff closed the investigation without recommending enforcement action.
  • Represented a biopharmaceutical company and current and former personnel in an SEC investigation relating to clinical trial data and securities trading, including presentations to the staff and preparation of witnesses for testimony.
  • Counsel to numerous private equity, investment management, and public company clients in SEC inquiries and enforcement actions involving a range of issues, including insider trading, accounting fraud, and other disclosure issues.
  • Represented multiple private equity and investment management clients in connection with SEC and DOL examinations and enforcement matters relating to ERISA fiduciary governance.
  • Conducted an internal investigation on behalf of a private equity firm into allegations of criminal misconduct by a former senior executive.

Pro Bono

  • Part of trial team that represented plaintiffs in a class action lawsuit against a state-run juvenile treatment facility, alleging violations of the Eighth and Fourteen Amendments arising out of excessive and punitive use of solitary confinement and fixed mechanical restraints.  Ropes & Gray, along with co-counsel Children’s Rights and Disability Rights Iowa, litigated the case through a two-week trial, securing sweeping injunctive relief under the Fourteenth Amendment and the appointment of a monitor.  Team was awarded firm-wide 2020 Pro Bono Team Award.
  • Part of litigation team that represented criminal defendant in a wrongful conviction matter, securing an Alford plea, with a sentence of time served, following grant of petition for writ of actual innocence based on DNA evidence undermining homicide convictions and life sentences from trials in 1981 and 1983.  Team was awarded firm-wide 2018 Pro Bono Team Award.

Areas of Practice